“You have the opportunity to help one patient in front of you when you are a clinician, but when working in the laboratory you have the opportunity to help millions of patients when you make a ground-breaking discovery.” Dr Mary Ann Anderson. Congratulations to Gandel Philanthropy-Snowdome Foundation Fellow, Dr Mary Ann Anderson, on winning the … Continued
In December 2018 the Australian Therapeutic Goods Administrator (TGA) approved the use of chimeric antigen receptor T cell (CAR-T cell) therapy for two types of blood cancer, diffuse large B cell lymphoma (DLBCL) and B cell precursor acute lymphoblastic leukaemia (ALL). CAR-T cell therapy involves extracting some of the patients T-cells (white blood cells that … Continued
Genomics, genetics and epigenetics seem to be buzzwords in the medical research area, especially when it comes to finding new treatments and ways to attack cancer. Researchers talk about mutations, malfunctioning genes, over expressed genes and provide you with a string of letters and numbers that are ‘misbehaving’. So, what does all this mean when … Continued
Just like every snowflake Snowdome Foundation is unique. We are the only organisation that is exclusively focused on funding blood cancer research to help Australian patients live a longer, better life. We are extremely proud of the work being conducted at the Christine and Bruce Wilson Centre for Lymphoma Genomics at the Peter MacCallum Cancer Centre not … Continued
The 2018 ‘Bloody Good Dinner’ raised almost $740,000 for the Snowdome Foundation and Maddie’s Vision to direct towards essential research into blood cancer and bone marrow failure. One of the important projects that the Boards of both organisations sought to fund was a National Career Development Fellowship for a woman in haematology. Women have well … Continued
Wonderful news for multiple myeloma patients with interim results of a new clinical trial (MAIA) reporting positive outcomes. Multiple myeloma patients who were not candidates for high dose chemotherapy or autologous stem cell transplants were treated with daratumumab (monoclonal antibody) in combination with lenalidomide and dexamethasone or with just lenalidomide and dexamethasone. Patients in the … Continued